Written by Sean Kimbrough, Founder & Executive Director, Courage Against Cancer
Sourced from peer-reviewed and IRB-registered clinical research · Last updated July 16, 2026
The Wellness Company’s Dr NICOLAS HULSCHER was a lead researcher in a study of 197 cancer patients taking compounded varieties of Ivermectin and Menebedazole for 6 months. It was not a structured clinical trial, but rather a cohort study, where the patients were instructed how much and when to take the mdiccations, record their oncology visit findings, and submit their 6 month test results.
Even though the results are extremely promising, there are some concerns as to the methods of the study.
CAC’s Take on the Study…
Comments:
I would enjoy your comment on this topic. Are these types of studies needed in more formal clinical trial format? Are more of these studies sufficient for presentation to FDA?
Read the study for yourself > Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort
What are your thoughts?
Medical Disclaimer
This article is produced by Courage Against Cancer (CAC) for educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. No information presented here should be used to initiate, modify, or discontinue any cancer therapy without first consulting a qualified oncologist or licensed healthcare provider. Courage Against Cancer (CAC) does not endorse any specific treatment protocol.
About This Content: This article was written and curated by CAC’s founder, drawing on peer-reviewed and IRB-registered clinical research. CAC is in the process of establishing a formal Medical Review Board and will update our content review process as reviewers join. This content is for educational purposes only and is not medical advice — always consult your healthcare team before making treatment decisions.